Introduction
The discovery of a safe and highly effective cure for Chronic Hepatitis C is perhaps one of the intriguing biotech success stories of the decade. Over the course of 20 years, the standard of care for Hepatitis C had evolved from a combined course of ribavarin and pegylated interferon to direct-acting antiviral ((DAA)) therapies. The switch from broad-spectrum therapeutics to specific viral Hepatitis C protein inhibitors effectively raised cure rates from 60% to almost 100% across all Hepatitis C genotypes and has eliminated the infamously severe side effects associated with the former standard of